A5085863614- Renal cell carcinoma treatment
- Epigenetics and DNA Methylation
- Phagocytosis and Immune Regulation
- Cancer Immunotherapy and Biomarkers
- Bladder and Urothelial Cancer Treatments
- Cancer Genomics and Diagnostics
- Renal and related cancers
- Ferroptosis and cancer prognosis
- Crystallization and Solubility Studies
- X-ray Diffraction in Crystallography
- Pancreatic and Hepatic Oncology Research
- Neuropeptides and Animal Physiology
- Urinary and Genital Oncology Studies
- Advanced Image Processing Techniques
- Cancer Mechanisms and Therapy
- Advanced Computational Techniques and Applications
- Smart Agriculture and AI
- Enzyme function and inhibition
- Chromatin Remodeling and Cancer
- Outsourcing and Supply Chain Management
- Neuroendocrine Tumor Research Advances
- Elevator Systems and Control
- Generative Adversarial Networks and Image Synthesis
- Biomedical Text Mining and Ontologies
- Receptor Mechanisms and Signaling
Sichuan University
2023-2025
West China Hospital of Sichuan University
2023-2025
Changchun University of Science and Technology
2024
Guangzhou Huali College
2020
Guangdong University of Technology
2020
Academy of Military Transportation
2010
University of Oklahoma Health Sciences Center
1998
544 Background: Non-clear cell renal carcinoma (nccRCC) accounts for approximately 25% of all (RCC) and lacks standards care. More recent data suggests the efficacy anti-PD-(L)1 plus anti-CTLA-4 immune checkpoint inhibitors combined with tyrosine-kinase in RCC. Cadonilimab (AK104) is a first-in-class tetravalent bispecific antibody that targets both PD-1 CTLA-4, showing manageable safety profile favorable clinical benefits. Here we explore cadonilimab combination axitinib patients advanced...
500 Background: Fumarate hydratase–deficient renal cell carcinoma (FH-deficient RCC) is a rare subtype of kidney cancer characterized by FH-inactivating alterations. Studies have revealed highly immunogenic features in this lethal disease, providing molecular evidence for implement immune checkpoint inhibitor (ICI). Due to the nature FH-deficient RCC, significant proportion patients continue disease progression after receiving ICI combination therapy (ICI plus tyrosine kinase inhibitors,...
Abstract Purpose: Fumarate hydratase–deficient renal cell carcinoma (FH-deficient RCC) is a rare and lethal subtype of kidney cancer. However, the optimal treatments molecular correlates benefits for FH-deficient RCC are currently lacking. Experimental Design: A total 91 patients with from 15 medical centers between 2009 2022 were enrolled in this study. Genomic bulk RNA-sequencing (RNA-seq) performed on 88 45 untreated RCCs, respectively. Single-cell RNA-seq was to identify biomarkers...
Abstract Purpose The WHO’s classification of renal cell carcinoma (RCC) has transitioned from solely morphologic to an integrated molecular-defined with genotyping based on driver genes. One-third patients localized diseases eventually develop metastases. First-line treatments tyrosine kinase inhibitors and immunotherapies have shown promise in improving patient outcomes. This study aims assess the efficacy next-generation sequencing (NGS) guided therapy for metastatic (mRCC). Methods We...
Biomedical named entity recognition is of great significance in the field natural language processing.Deep learning approaches are mainly used at present, and BERT-BiLSTM-CRF model one them. Although BiLSTM structure this can capture bi-directional long-distance dependencies sentences, there problem that performance easily reach bottleneck by simply adjusting hyperparameters or changing network structure, quality its results hardly be further improved. To address above problems, paper adds...
Abstract Background The mutational pattern of homologous recombination repair (HRR)‐associated gene alterations in Chinese urothelial carcinoma (UC) necessitates comprehensive sequencing efforts, and the clinical implications HRR mutations UC remain to be elucidated. Materials Methods We delineated landscape 343 patients from West China Hospital 822 Cancer Genome Atlas (TCGA) using next‐generation (NGS). Data 182 metastatic MSK‐IMPACT cohort were used assess association between immunotherapy...
429 Background: Due to the rarity of TFE3-rearranged renal cell carcinoma ( TFE3-rRCC) and poor understanding its underlying mechanisms, clinical treatment landscape in TFE3-rRCC is largely undefined. Hence, optimal therapy for remains be determined. The diversity fusion partners leads high heterogeneity TFE3-rRCC, yet no studies have compared responses patients with different systemic treatment. Methods: Data were collected retrospectively from our institution. Patients metastatic eligible....
<div>AbstractPurpose:<p>Fumarate hydratase–deficient renal cell carcinoma (FH-deficient RCC) is a rare and lethal subtype of kidney cancer. However, the optimal treatments molecular correlates benefits for FH-deficient RCC are currently lacking.</p>Experimental Design:<p>A total 91 patients with from 15 medical centers between 2009 2022 were enrolled in this study. Genomic bulk RNA-sequencing (RNA-seq) performed on 88 45 untreated RCCs, respectively. Single-cell...
<p>Supplementary Figure 2. Treatment details and survival outcomes of patients with metastatic FH-deficient RCC. (A) Swimmer plot showing the treatment response duration each patient receiving first-line systemic treatments; (B) Progression-free for (C) Overall (OS) treatments.</p>
<p>Supplementary Figure 6. Validation of the FH-deficient RCC immune signature. (A) UMAP plot showing expression selected genes; (B) Correlations between six genes in signature and treatment response, significance differential (q value) was determined by two-sided Wilcoxon rank-sum test with Bonferroni FDR correction; (C) several related hallmark pathways, correction. *, q<0.05; **, q<0.01; ***, q<0.001; ****, q<0.0001.</p>
<p>Supplementary Figure 3. Forest plot showing the prognostic value of clinicopathologic and molecular features in patients treated with first-line ICI+TKI combination therapy. HR<1 indicates better survival comparator group, while HR>1 control group. TMB, tumor mutation burden; MUT, mutation; WT, wild type; TPS, proportion score; CCP, cell cycle progression; Sig., signature.</p>